BMEA|EPS -$1.18|Net Loss $61.8MCompany Overview
Biomea Fusion is a clinical-stage company developing oral small molecule therapies targeted at treating diabetes and obesity.
Key Financial Figures
For the year ended December 31, 2025, Biomea reported an EPS (net loss per common share, basic and diluted) of $(1.18).
Additional Financial Insights
Total operating expenses for the year were $83.5 million. Research and development expenses totaled $62.0 million for 2025. The company ended 2025 with $56.2 million in cash, cash equivalents, and restricted cash, which provides a projected cash runway into the first quarter of 2027.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.